Combined Analysis of CSF Tau, A𝛽42, A𝛽1–42% and A𝛽1–40^ox% in Alzheimer's Disease, Dementia with Lewy Bodies and Parkinson's Disease Dementia

Table 1

Age, MMSE, Total tau, A𝛽42, A𝛽1–42%, and A𝛽1–40^𝑜𝑥% in the CSF of the diagnostic groups.

Diagnosis	NDC (𝑛=40)	AD (𝑛=45)	DLB (𝑛=15)	PDD (𝑛=21)
	mean ± SD	mean ± SD	mean ± SD	mean ± SD
Age	64.5 ± 9.3	70.9 ± 9.2	71.4 ± 7.6	73.2 ± 7.2
MMSE	28.6 ± 1.4	19.4 ± 5.8	19.2 ± 3.0	18.1 ± 7.2
Total tau (ELISA)^1	0.23 ± 0.14	0.62 ± 0.34	0.37 ± 0.29	0.31 ± 0.24
A𝛽1–42 (ELISA)^1	0.79 ± 0.27	0.41 ± 0.14	0.37 ± 0.17	0.51 ± 0.22
A𝛽42/Tau (ELISA)^1	4.74 ± 3.03	0.87 ± 0.58	1.63 ± 1.35	3.16 ± 2.72
A𝛽1–42% (A𝛽-SDS-PAGE/immunoblot)^2	11.65 ± 3.53	4.38 ± 0.89	7.13 ± 2.13	7.54 ± 2.07
A𝛽1–42% (A𝛽-SDS-PAGE/immunoblot)^2	0.77 ± 0.5	0.88 ± 0.27	1.78 ± 0.70	1.05 ± 0.48

¹A𝛽 peptide concentrations as measured by ELISA (ng/ml or ratio)
²A𝛽 peptide values of A𝛽1–42 and A𝛽1–40^ox, respectively, relative to the sum of all measurable A𝛽 peptides in the A𝛽-SDS-PAGE/ immunoblot